Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Virdante Pharmaceuticals Inc.

www.virdante.com

Latest From Virdante Pharmaceuticals Inc.

Cydan Hopes To Accelerate Rare Disease Drug Development With $16M Raise

The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.

BioPharmaceutical North America

Deals Shaping The Medical Industry (01/2012)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Johnson & Johnson/Pharmacyclics, AstraZeneca/Guangdong BeiKang, AstraZeneca/Medical Research Council

As more and more biopharmaceutical companies jump on the biosimilars train, the complexities of this emerging business area are becoming clear.

BioPharmaceutical Deals

Virdante Pharmaceuticals Inc.

Virdante Pharmaceuticals aims to improve the anti-inflammatory properties of antibodies with proprietary "sialic switch" technology developed by scientific founder Jeffrey Ravetch, MD, PhD, at Rockefeller University. If the process can be scaled up, Virdante thinks it will be possible to create products that are safer and more effective at treating inflammatory and autoimmune disorders.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Centaurus Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Virdante Pharmaceuticals Inc.
  • Senior Management
  • John Ripple, CEO
    Cristina Csimma, VP, Drug. Dev.
  • Contact Info
  • Virdante Pharmaceuticals Inc.
    Phone: (617) 300-8500
    14 Cambridge Ctr.
    Bldg. 1
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register